Sertraline belongs to the SSRIs, the class defined by selective inhibition of the presynaptic Serotonin transporter (SERT, SLC6A4) with comparatively little affinity for the norepinephrine or dopamine transporters at therapeutic concentrations. Blockade of SERT raises synaptic serotonin in the short term, but the clinically relevant effect — the one that tracks with symptom remission rather than the first dose — is the cascade of receptor adaptations that follows over two to six weeks. Presynaptic 5-HT1A autoreceptors desensitize, firing rates in dorsal raphe neurons normalize, and downstream postsynaptic signaling shifts in ways that map onto improvement in depression and anxiety. This delay between transporter blockade and clinical response is the single most important fact to communicate to a patient starting any SSRI.

Within the SSRI class sertraline is distinguished by two pharmacologic quirks. First, it has modest dopamine transporter (DAT) affinity, weaker than its SERT activity by roughly an order of magnitude but greater than that of fluoxetine, paroxetine, citalopram, or escitalopram. Whether this DAT effect contributes to the drug's somewhat activating clinical profile remains debated; it is unlikely to produce stimulant-like effects at standard doses but is occasionally invoked to explain why some patients tolerate sertraline better than the more sedating SSRIs (Stahl, 2021) [VERIFY]. Second, sertraline has weak sigma-1 receptor activity, the clinical significance of which is unclear.

What sertraline largely lacks is just as important. It has minimal affinity for muscarinic, histaminergic H1, or alpha-1 adrenergic receptors at therapeutic doses, which translates clinically into far less anticholinergic burden, sedation, and orthostasis than the tricyclics it replaced. Compared with paroxetine, sertraline causes less weight gain and less anticholinergic effect; compared with fluoxetine, it has a much shorter half-life and no clinically active long-lived metabolite. Compared with citalopram and escitalopram, it carries less QT-prolongation risk at standard doses.

Sertraline holds six FDA-approved indications, more than any other SSRI: Major depressive disorder in adults, Obsessive-compulsive disorder in adults and children aged 6 and older, Panic disorder, Posttraumatic stress disorder, Social anxiety disorder, and Premenstrual dysphoric disorder. The breadth matters less for any single patient than for the prescribing primary-care physician who can manage most of an outpatient anxiety and depression clinic with one drug they understand well.

First-line pharmacotherapy

Sertraline is named as a first-line option in essentially every major mood and anxiety guideline, alongside other SSRIs and SNRIs. The CANMAT 2016 guidelines list sertraline among first-line antidepressants for MDD on the strength of comparative efficacy and tolerability data (Kennedy et al., 2016) [VERIFY]. The Cipriani network meta-analysis of 21 antidepressants placed sertraline favorably on the efficacy-acceptability frontier, supporting its clinical reputation as a reasonable default choice (Cipriani et al., 2018) [VERIFY]. NICE guidance for depression and the various anxiety disorders likewise position sertraline as a first-line SSRI (NICE, NG222, 2022) [VERIFY].

Approved indications and typical dose ranges

Off-label uses with reasonable evidence

Sertraline is widely used off-label for generalized anxiety disorder, where the SSRI class effect is well established and sertraline performs comparably to escitalopram and paroxetine. It is reasonable for body dysmorphic disorder, where SSRIs at OCD-range doses are first-line, and for hoarding disorder along similar lines. Body-focused repetitive behavior disorders such as trichotillomania and skin-picking disorder respond inconsistently to SSRIs; sertraline is sometimes tried but N-acetylcysteine has comparable evidence with fewer side effects.

Beyond psychiatry, sertraline is used for vasomotor symptoms of menopause (less effective than venlafaxine or paroxetine) and as a second-line agent in irritable bowel syndrome with prominent depressive or anxious features. The FDA approves paroxetine, not sertraline, for menopausal vasomotor symptoms; the off-label distinction matters when documenting indication.

Sertraline is well absorbed orally, with peak plasma concentrations 4 to 8 hours after a dose. Food increases absorption modestly and raises Cmax by about 25 percent, which is why the label recommends a consistent relationship to meals; in practice, dosing with food also reduces the GI upset patients describe in the first week. The drug is highly protein-bound, around 98 percent, and distributes widely. Steady state is reached after approximately one week of consistent dosing in adults, with a longer interval (two to three weeks) in older adults and patients with hepatic impairment.

Hepatic metabolism is extensive and proceeds through several CYP enzymes including CYP2B6, CYP2C19, CYP2C9, CYP2D6, and CYP3A4, with CYP2B6 making the largest single contribution. The breadth of pathways is clinically useful: a single CYP inhibitor or inducer rarely produces dramatic changes in sertraline levels, in contrast to drugs metabolized through a single dominant route. The principal metabolite, N-desmethylsertraline, has only a fraction of the parent compound's SERT affinity and is not considered clinically active in the way fluoxetine's norfluoxetine is.

Elimination half-life is roughly 26 hours for the parent compound, supporting once-daily dosing. N-desmethylsertraline has a longer half-life of approximately 62 to 104 hours but contributes negligibly to clinical effect. Sertraline is excreted in roughly equal proportions in urine and feces as metabolites, with less than 1 percent of the parent drug excreted unchanged. The relatively short half-life relative to fluoxetine makes sertraline easier to wash out before MAOI initiation (a 14-day washout suffices) and makes discontinuation symptoms more likely if doses are missed for several days, particularly at higher doses.

Sertraline is supplied as 25, 50, and 100 mg scored tablets and as a 20 mg/mL oral concentrate; the latter is useful when titrating in pediatric patients or when very small doses are needed. The oral concentrate must be diluted in water, ginger ale, lemon-lime soda, lemonade, or orange juice immediately before administration; alcohol-containing diluents are contraindicated.

Starting dose and titration

For most adult indications other than panic disorder and PTSD, the standard starting dose is 50 mg once daily. The dose can be increased by 25 to 50 mg increments at intervals of at least one week, guided by tolerability and response. For panic disorder, where early activation can mimic the symptoms patients are seeking treatment for, start at 25 mg daily for the first week and increase to 50 mg in week two. The same low-and-slow approach is reasonable in PTSD, generalized anxiety disorder, and in patients with prominent somatic anxiety or a history of poor SSRI tolerability.

Target dose and dose-response

For depression, panic disorder, and social anxiety disorder, dose-response is relatively flat above 50 to 100 mg in most patients; raising the dose further is appropriate when partial response is present but should not be the reflexive next step in non-responders. For OCD, the dose-response curve is steeper and most patients require 150 to 200 mg daily, sometimes with a longer time course (10 to 12 weeks) before adequate response can be judged. PMDD can be treated either continuously or intermittently in the luteal phase only; the latter strategy uses 50 to 100 mg daily starting roughly 14 days before menses and stopping at menses, with comparable efficacy to continuous dosing in placebo-controlled trials.

Maximum dose

The FDA-labeled maximum is 200 mg/day for all indications. Doses above 200 mg are sometimes used in OCD specialist clinics, but evidence for additional benefit beyond 200 mg is weak and most clinicians switch to a different SSRI or augment rather than escalate further.

Special populations

In hepatic impairment, both Cmax and AUC roughly triple in patients with mild cirrhosis; halve the starting dose and titrate more slowly, or consider an alternative agent in moderate-to-severe impairment. Renal impairment does not require dose adjustment as the drug is essentially completely metabolized before excretion. In older adults, start at 25 mg and titrate slowly; the geriatric dose range is similar to the adult range but with greater attention to hyponatremia risk. In children with OCD aged 6 to 12, start at 25 mg daily; in adolescents (13 to 17), start at 50 mg.

Discontinuation

Taper to reduce discontinuation symptoms (dizziness, paresthesias, vivid dreams, flu-like sensations, the so-called "brain zaps"). A reasonable schedule reduces by 25 to 50 mg every one to two weeks, slower at lower doses. Patients on 200 mg may need a multi-month taper; a 25 mg drop from 25 to 0 is often the hardest step and may need to be bridged with the oral concentrate or alternate-day dosing.

Common effects (>1%)

Gastrointestinal symptoms dominate the early-treatment side-effect profile. Nausea, loose stools, and dyspepsia occur in roughly 20 to 30 percent of patients in the first one to two weeks and usually attenuate with continued dosing. Diarrhea is more characteristic of sertraline than of other SSRIs and is occasionally persistent enough to force a switch. Insomnia, jitteriness, and a sense of inner restlessness early in treatment reflect the drug's activating profile; dosing in the morning helps, and brief co-administration of a benzodiazepine or hydroxyzine in the first one to two weeks is appropriate when activation threatens adherence in an anxious patient.

Sexual dysfunction is the side effect that drives the most discontinuations once acute GI symptoms settle. Decreased libido, delayed ejaculation, anorgasmia, and erectile dysfunction occur in 30 to 70 percent of patients depending on how the question is asked; population-based estimates are reliably higher than clinical trial spontaneous-report figures. The effect is dose-related, persists for the duration of treatment in most patients, and resolves on discontinuation, though a small subset reports Post-SSRI sexual dysfunction persisting after discontinuation. Headache, dry mouth (less than with TCAs), tremor, sweating, and modest weight changes are also common. Sertraline tends to be weight-neutral or slightly weight-reducing in short-term trials but produces clinically meaningful weight gain in some patients on longer-term treatment.

Serious effects

Hyponatremia, usually due to SIADH, occurs in older adults and patients on diuretics; it can present subtly with fatigue, headache, or confusion or dramatically with seizures. Check a baseline sodium in older adults and recheck within two to four weeks of initiation or any meaningful dose change. Serotonin syndrome from sertraline alone is rare but real, and the risk rises with combinations: MAOIs (contraindicated), linezolid, methylene blue, tramadol, fentanyl, dextromethorphan, triptans, St John's wort, and MDMA. The clinical triad of mental status change, neuromuscular hyperactivity (clonus, hyperreflexia, tremor), and autonomic instability emerges within hours to days of the precipitating exposure.

Bleeding risk is a class effect of SSRIs and reflects platelet serotonin depletion with consequent reduction in platelet aggregation. Sertraline approximately doubles the risk of upper GI bleeding, and the risk compounds when combined with NSAIDs, aspirin, or anticoagulants; co-prescription of a proton pump inhibitor is reasonable when the combination is necessary. Perioperatively, the absolute increase in bleeding risk is modest and most surgeons no longer require SSRI cessation, but the conversation with the surgical team should happen before elective procedures with high bleeding stakes.

QT prolongation is dose-related and clinically minor at standard doses for sertraline, in contrast to citalopram where the FDA capped the dose at 40 mg (20 mg in older adults or CYP2C19 poor metabolizers) on QT grounds. Sertraline does not carry an analogous dose cap. Bradycardia and syncope are uncommon. Mania or hypomania can be precipitated in patients with undiagnosed bipolar disorder; screen for prior manic or hypomanic episodes before starting any antidepressant. Bruxism, hair thinning, and a small increase in fracture risk in older adults round out the list of effects that occasionally surface in long-term treatment.

Rare but must-recognize:

Serotonin syndrome (above) is the emergency to recognize. Acute angle-closure glaucoma can be precipitated rarely; counsel patients with a history of narrow angles. Hepatotoxicity is rare and usually mild. Akathisia, more familiar from antipsychotics, occurs in a minority of patients on SSRIs and is sometimes mistaken for worsening anxiety or agitation; the distinction matters because raising the dose of the offending drug worsens akathisia.

Absolute contraindications

Concurrent use of an MAOI, or use within 14 days of stopping an MAOI, is contraindicated because of serotonin syndrome risk. The same prohibition applies to linezolid and intravenous methylene blue, both of which are potent reversible MAOIs whose psychotropic indications are usually unrelated to depression. Pimozide co-administration is contraindicated owing to QT and metabolic interaction concerns. The oral concentrate is contraindicated with disulfiram because of its alcohol content.

Relative contraindications and high-caution scenarios

A patient with a known or suspected Bipolar I disorder or Bipolar II disorder who has not been adequately mood-stabilized should not be started on any SSRI as monotherapy, because of the risk of antidepressant-induced mania and the broader question of whether SSRI monotherapy worsens long-term illness course in bipolar depression. The STEP-BD findings argued against routine antidepressant addition for bipolar depression on top of a mood stabilizer (Sachs et al., 2007) [VERIFY].

Hepatic impairment requires dose reduction and slower titration; severe impairment is a reasonable contraindication. A history of bleeding disorder, recent intracranial hemorrhage, or active peptic ulcer disease are relative contraindications, particularly in combination with NSAIDs or anticoagulants. A QTc above 500 ms or a clinically meaningful arrhythmia raises caution but does not strictly contraindicate sertraline at standard doses, in contrast to citalopram.

There is no REMS program for sertraline. The black-box warning for suicidality in patients under 25 applies, requires Medication Guide distribution, and should be the subject of an explicit informed-consent conversation at initiation, particularly in adolescents and young adults.

Sertraline is a mild-to-moderate inhibitor of CYP2D6, weaker than paroxetine or fluoxetine but clinically relevant at doses above 100 mg. It also weakly inhibits CYP2B6, CYP2C9, CYP2C19, and CYP3A4. The drug is itself a substrate of multiple CYP enzymes (predominantly CYP2B6), which limits the impact of any single inhibitor or inducer. The interactions worth memorizing fall into three groups: serotonergic combinations, bleeding-risk combinations, and metabolic interactions of clinical magnitude.

Serotonergic combinations

MAOIs, linezolid, and intravenous methylene blue are absolute contraindications as above. The combinations that require caution rather than avoidance include tramadol, fentanyl and other meperidine-class opioids, dextromethorphan, triptans, ondansetron and other 5-HT3 antagonists at high dose, lithium, buspirone, mirtazapine, trazodone, and other antidepressants. The risk in any individual combination is generally low at therapeutic doses, but cumulative serotonergic burden matters and the threshold for serotonin syndrome falls when several agents are combined or when one is added at high dose. St John's wort is a particular trap because patients often do not disclose herbal use.

Bleeding combinations

NSAIDs, aspirin, clopidogrel, warfarin, and the direct oral anticoagulants all compound the platelet-related bleeding risk of SSRIs. The combination is not contraindicated but warrants explicit counseling and, when ongoing, a proton pump inhibitor for GI protection.

Metabolic interactions of clinical magnitude

Of the SSRIs, sertraline is the preferred agent in patients on tamoxifen because it inhibits CYP2D6 less than paroxetine or fluoxetine and therefore preserves more of the conversion of tamoxifen to its active metabolite endoxifen. When co-prescription is unavoidable, sertraline at low to moderate doses is the conventional choice, though escitalopram and citalopram inhibit CYP2D6 even less and are reasonable alternatives if QT considerations permit.

Baseline

Sertraline is one of the few psychotropics that requires very little baseline laboratory work in an otherwise healthy adult. A reasonable baseline panel includes BMP (sodium in particular), CBC, and TSH if not recently checked, more for differential-diagnostic reasons than drug safety. An EKG is not routinely required at standard doses but is appropriate in patients with cardiac history, electrolyte abnormalities, or co-prescription with QT-prolonging drugs. Pregnancy testing is appropriate in patients of reproductive potential when clinically indicated.

During titration

There are no required drug levels. Recheck sodium within two to four weeks of initiation in older adults, in patients on diuretics, and in patients with low-normal baseline sodium. Re-evaluate at one to two weeks for tolerability, then at four to six weeks for early response, and at eight to twelve weeks to judge full response. Sleep, suicidality, activation, and sexual function should be asked about specifically at each visit; patients underreport sexual side effects unless prompted.

Maintenance

Annual sodium and basic chemistries are reasonable in older adults on long-term sertraline. There is no validated therapeutic plasma level for sertraline; level monitoring is reserved for adherence questions or suspected pharmacokinetic anomalies and is not part of routine care. Re-evaluate the need for ongoing treatment annually, balancing the recurrence risk for the underlying disorder against the cumulative side-effect burden.

Pregnancy

Sertraline is among the better-studied antidepressants in pregnancy and is widely considered a reasonable first choice when an SSRI is needed. The old FDA pregnancy categories have been replaced by the Pregnancy and Lactation Labeling Rule, but sertraline was historically Category C. The clinically meaningful concerns are not major teratogenicity (large datasets do not show a clear signal at the population level) but rather three peripartum issues. First, neonatal adaptation syndrome — irritability, jitteriness, transient feeding difficulty, respiratory distress — affects roughly one-quarter of late-pregnancy SSRI-exposed neonates and is usually self-limited within days. Second, persistent pulmonary hypertension of the newborn (PPHN) shows a small absolute risk increase with late-pregnancy SSRI exposure (numbers needed to harm in the hundreds to low thousands). Third, untreated maternal depression is itself associated with adverse pregnancy and neonatal outcomes, and the decision to continue or initiate sertraline in pregnancy belongs to a careful risk-benefit conversation rather than a reflex toward discontinuation. The ACOG and APA joint position has consistently been that the decision is individualized and that abrupt discontinuation in a patient with a serious depressive history is rarely the right answer (ACOG Committee Opinion, 2008) [VERIFY].

Lactation

Sertraline has the most reassuring lactation data of the SSRIs. Levels in breast milk are low and infant serum concentrations are typically undetectable or near the assay limit. It is a first-line choice when a breastfeeding patient requires antidepressant therapy.

Pediatrics

Sertraline is FDA-approved for OCD in children aged 6 and older but not for pediatric depression, where fluoxetine and escitalopram hold the depression-specific approvals. It is nonetheless used off-label for adolescent anxiety disorders with reasonable evidence. The black-box warning for suicidality applies, and clinicians should arrange close follow-up — weekly contact in the first month is a defensible standard, even if not formally required. Start at 25 mg in children 6 to 12 and at 50 mg in adolescents.

Geriatrics

Older adults tolerate sertraline well in general, but two issues dominate: hyponatremia and falls. Start at 25 mg, titrate slowly, and check sodium at baseline and within a month of any dose change. Sertraline carries the lowest anticholinergic burden of any SSRI on most rating systems and is preferred over paroxetine in patients vulnerable to anticholinergic effects (the Beers Criteria explicitly recommend against paroxetine in older adults; sertraline is not on the avoid list).

Hepatic and renal impairment

In hepatic impairment, half-life roughly doubles and AUC triples; halve the starting dose and titrate by smaller increments at longer intervals. In renal impairment, no dose adjustment is needed because of the drug's predominantly metabolic clearance. The drug is not removed by hemodialysis to a clinically significant extent.

Sertraline is generic across all standard formulations and is among the least expensive psychotropics in the United States, with cash prices typically under twenty dollars a month at major pharmacies even without insurance. The 25, 50, and 100 mg tablets are all on virtually every formulary at the lowest tier, and prior authorization is essentially never required. The oral concentrate is more expensive and occasionally requires brand justification or a specialty pharmacy fill, but it is also less commonly needed. The combination of broad indication, generic pricing, and minimal prior-authorization friction is a major reason sertraline retains its dominant position in primary-care antidepressant prescribing.

Brand name (Zoloft) is essentially never necessary; a request for brand should prompt a conversation about why generic is unacceptable, since bioequivalence data are robust and the cost differential is substantial.

• Sertraline has the broadest FDA-approved indication list of any SSRI: MDD, OCD (children >=6 and adults), panic disorder, PTSD, social anxiety disorder, PMDD.
• Standard adult starting dose is 50 mg daily; 25 mg in panic disorder and in older adults to reduce early activation.
• OCD typically requires higher doses (150 to 200 mg) and a longer trial (10 to 12 weeks) than MDD.
• FDA-labeled maximum is 200 mg/day across all indications.
• Half-life is approximately 26 hours (parent compound); steady state in about one week.
• Metabolized through multiple CYPs (CYP2B6 dominant); inhibits CYP2D6 mildly to moderately, less than paroxetine or fluoxetine.
• Preferred SSRI in patients on tamoxifen because of comparatively weak CYP2D6 inhibition.
• 14-day washout required when switching to or from an MAOI.
• Black-box warning: increased suicidal ideation in patients under 25.
• Contraindicated with MAOIs, linezolid, IV methylene blue, and pimozide; oral concentrate contraindicated with disulfiram (alcohol content).
• Sertraline is the preferred SSRI in pregnancy and in lactation among practitioners who individualize the risk-benefit conversation; lactation data are particularly favorable.
• Common adverse effects: GI upset (especially diarrhea), insomnia or activation early, sexual dysfunction (dose-related), headache, hyperhidrosis.
• Hyponatremia (SIADH) and bleeding risk are class effects of clinical importance, particularly in older adults and patients on NSAIDs or anticoagulants.
• Discontinuation syndrome occurs with abrupt cessation; taper over weeks, slower at lower doses.
• Unlike citalopram, sertraline has no FDA-mandated dose cap for QT concerns.
• Hepatic impairment: halve starting dose and titrate slowly. Renal impairment: no adjustment.
• Generic, very inexpensive, on essentially every formulary at the lowest tier.